Table 3.
Univariate and multivariate survival analysis for gastric cancer-specific survival (CSS) predictors. SEER 2004-2012 (n=12216)
| Variable | Univariate Analysis | Multivariate Analysis | |||||
|---|---|---|---|---|---|---|---|
| 3-year CSS | Log rank χ2 | P Value | HR | 95%CI | P Value | ||
| Age | 7.89 | 0.005 | |||||
| <50 | 56.60% | Reference | |||||
| ≥50 | 52.77% | 1.32 | 1.20-1.45 | <0.001 | |||
| Primary Site | 235.07 | <0.001 | |||||
| Fundus of stomach | 44.60% | Reference | |||||
| Body of stomach | 54.74% | 0.92 | 0.79-1.07 | 0.264 | |||
| Gastric antrum | 57.12% | 0.9 | 0.79-1.03 | 0.132 | |||
| Pylorus | 51.35% | 1.04 | 0.88-1.24 | 0.625 | |||
| Lesser curvature of stomach, NOS | 61.48% | 0.76 | 0.65-0.88 | <0.001 | |||
| Greater curvature of stomach, NOS | 56.10% | 1.01 | 0.85-1.19 | 0.943 | |||
| Overlapping lesion of stomach | 39.67% | 1.01 | 0.87-1.17 | 0.879 | |||
| Stomach, NOS | 43.55% | 1.08 | 0.93-1.24 | 0.302 | |||
| Sex | 5.45 | 0.0195 | |||||
| Male | 54.01% | Reference | |||||
| Female | 52.19% | 0.97 | 0.91-1.03 | 0.283 | |||
| Race | 152.62 | <0.001 | |||||
| White | 50.28% | Reference | |||||
| Black | 49.28% | 1.03 | 0.95-1.11 | 0.517 | |||
| American Indian/Alaska Native | 46.62% | 1.06 | 0.81-1.39 | 0.685 | |||
| Asian or Pacific Islander | 63.25% | 0.76 | 0.71-0.82 | <0.001 | |||
| Unknown | 83.28% | 0.38 | 0.17-0.84 | 0.017 | |||
| Marital status | 107.47 | <0.001 | |||||
| Married | 56.30% | Reference | |||||
| Single (never married) | 50.86% | 1.07 | 0.98-1.17 | 0.118 | |||
| Divorced/Separated | 52.42% | 1.07 | 0.96-1.18 | 0.229 | |||
| Widowed | 45.41% | 1.33 | 1.23-1.44 | <0.001 | |||
| Grade | 268.73 | <0.001 | |||||
| Grade I | 79.71% | Reference | |||||
| Grade II | 62.46% | 1.46 | 1.19-1.80 | <0.001 | |||
| Grade III | 48.81% | 1.86 | 1.52-2.28 | <0.001 | |||
| Grade IV | 42.75% | 2.31 | 1.77-3.02 | <0.001 | |||
| Cell type not determined | 47.57% | 1.44 | 1.15-1.80 | 0.001 | |||
| Histological type | 167.02 | <0.001 | |||||
| Adenocarcinoma, NOS | 52.88% | Reference | |||||
| Adenocarcinoma, intestinal type | 65.74% | 0.86 | 0.78-0.94 | 0.001 | |||
| Carcinoma, diffuse type | 46.65% | 1.14 | 1.01-1.28 | 0.029 | |||
| Tubular adenocarcinoma | 60.76% | 1.16 | 0.88-1.54 | 0.297 | |||
| Papillary adenocarcinoma, NOS | 75.24% | 0.96 | 0.55-1.66 | 0.879 | |||
| Mucinous adenocarcinoma | 51.56% | 0.95 | 0.77-1.18 | 0.662 | |||
| Signet ring cell carcinoma | 46.73% | 1.11 | 1.04-1.19 | 0.003 | |||
| Stagea | 935.68 | <0.001 | |||||
| I | 71.28% | Reference | |||||
| II | 54.39% | 1.93 | 1.78-2.11 | <0.001 | |||
| III | 33.04% | 3.12 | 2.83-3.44 | <0.001 | |||
| Surgery | 1882.3 | <0.001 | |||||
| No surgery | 18.13% | Reference | |||||
| Non-Total or Non-near-total gastrectomy | 62.31% | 0.32 | 0.28-0.36 | <0.001 | |||
| Total or near total gastrectomy | 49.91% | 0.37 | 0.32-0.43 | <0.001 | |||
| Radiation | 14.32 | <0.001 | |||||
| No radiotherapy | 53.32% | Reference | |||||
| Radiotherapy | 53.57% | 0.64 | 0.60-0.69 | <0.001 | |||
| Radiotherapy unknown | 47.95% | 0.91 | 0.73-1.12 | 0.357 | |||
Abbreviation: NOS= no other specific; SEER=Surveillance, Epidemiology and End Results
aBeing restaged according to the criteria of AJCC Cancer Staging Manual (7th edition, 2010)